8 active not recruiting, 5 recruiting, 1 completed, 1 not yet recruiting. 16 Phase 1, 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 16 | Active not recruiting 8, Recruiting 5, Completed 1, Not yet recruiting 1, Terminated 1 |
| Phase 2 | 8 | Active not recruiting 4, Recruiting 3, Completed 1 |
Follow amivantamab: new trials by email Literature Review of amivantamab trials Research Report on amivantamab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| JIN-A02 Plus Amivantamab in EGFR-Mutant NSCLC After Third-Generation EGFR-TKI Failure JIN-A02 in Combination with Amivantamab - Carcinoma, Non-Small-Cell Lung | Phase 1 | Not yet recruiting | Yonsei University | 36 | 2026-09-28 | 2026-09-02 |
| A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer Amivantamab, Olomorasib - Carcinoma, Non-Small-Cell Lung | Phase 1 / Phase 2 | Recruiting | Janssen Research & Development, LLC | 60 | 2026-03-03 | 2026-09-25 |
| A Study of JNJ-95437446 in Participants With Advanced-Stage Solid Tumors JNJ-95437446, Amivantamab - Advanced Stage Solid Tumors | Phase 1 | Recruiting | Janssen Research & Development, LLC | 400 | 2025-07-15 | 2026-09-29 |
| ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC ORIC-114 Dose 1 + amivantamab, ORIC-114 Dose 2 + amivantamab, ORIC-114 Dose 3 + amivantamab - Solid Tumors, EGFR Exon 20 Insertion Mutations | Phase 1 | Recruiting | ORIC Pharmaceuticals | 76 | 2025-02-27 | 2026-04-24 |
| 5G-EMERALD: Amivantamab in Malignant Brain Tumours Amivantamab - Malignant Primary Gliomas, Glioblastoma Multiform (Grade IV Astrocytoma) | Phase 1 | Active not recruiting | Institute of Cancer Research, United Kingdom | 12 | 2024-10-09 | 2026-08-17 |
| A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer Amivantamab, Docetaxel - Carcinoma, Non-Small-Cell Lung | Phase 1 / Phase 2 | Completed | Janssen Research & Development, LLC | 12 | 2024-07-23 | 2026-07-31 |
| PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer Amivantamab, Tepotinib - Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 3 | 2024-06-18 | 2026-09-11 |
| A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies KQB198, Osimertinib, Amivantamab - Solid Tumor, Adult | Phase 1 | Active not recruiting | Kumquat Biosciences Inc. | 92 | 2024-06-03 | 2026-09-02 |
| A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer Amivantamab, Pembrolizumab, Paclitaxel - Squamous Cell Carcinoma of Head and Neck | Phase 1 / Phase 2 | Recruiting | Janssen Research & Development, LLC | 287 | 2024-04-22 | 2026-09-25 |
| Amivantamab With Tyrosine Kinase Inhibitors (TKI) for Advanced NSCLC With ALK, ROS1, or RET Alterations Amivantamab 1050mg, Amivantamab 1400mg, Amivantamab (to be determined) - Lung Cancer, Non Small Cell Lung Cancer | Phase 1 / Phase 2 | Active not recruiting | University of Colorado, Denver | 12 | 2023-07-17 | 2026-09-29 |
| A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer Cetrelimab, Amivantamab - Carcinoma, Non-Small-Cell Lung | Phase 1 / Phase 2 | Active not recruiting | Janssen Research & Development, LLC | 71 | 2023-05-18 | 2026-09-25 |
| A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer Capmatinib, Amivantamab - Carcinoma, Non-Small-Cell Lung | Phase 1 / Phase 2 | Active not recruiting | Janssen Research & Development, LLC | 57 | 2022-12-13 | 2026-09-25 |
| A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer Amivantamab IV, Fluorouracil, Leucovorin - Advanced or Metastatic Colorectal Cancer | Phase 1 / Phase 2 | Recruiting | Janssen Research & Development, LLC | 225 | 2022-07-29 | 2026-09-25 |
| FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors FT536, Cyclophosphamide, Fludarabine - Non Small Cell Lung Cancer, Colorectal Cancer | Phase 1 | Terminated | Fate Therapeutics | 5 | 2022-05-31 | 2023-09-21 |
| A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer Lazertinib, Amivantamab, Carboplatin - Carcinoma, Non-Small-Cell Lung | Phase 1 | Active not recruiting | Janssen Research & Development, LLC | 701 | 2019-09-04 | 2026-07-06 |
| Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer Amivantamab, Lazertinib, Carboplatin - Non-Small-Cell Lung Cancer | Phase 1 | Active not recruiting | Janssen Research & Development, LLC | 751 | 2016-05-24 | 2026-09-25 |
Carcinoma, Non-Small-Cell Lung (9) · Colorectal Neoplasms (2) · Breast Neoplasms (1) · Carcinoma (1) · Glioblastoma (1) · Head and Neck Neoplasms (1) · Lung Neoplasms (1) · Ovarian Neoplasms (1) · Pancreatic Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1)
Janssen Research & Development, LLC (9) · Fate Therapeutics (1) · Institute of Cancer Research, United Kingdom (1) · Kumquat Biosciences Inc. (1) · M.D. Anderson Cancer Center (1) · ORIC Pharmaceuticals (1) · University of Colorado, Denver (1) · Yonsei University (1)
United States (14) · South Korea (8) · Spain (8) · China (6) · United Kingdom (6) · Canada (5) · France (5) · Italy (5) · Taiwan (5) · Germany (4) · Japan (4) · Turkey (Türkiye) (4) · Malaysia (3) · Poland (3) · Australia (2)
Erin Schenk, MD, PhD (1) · Juanita Lopez, MD, PhD (1) · Pratik S. Multani, MD, MS (1) · Xiuning Le, MD,PHD (1)
PMID 34339261, PMID 34339292, PMID 35963523, PMID 36652175, PMID 37022784, PMID 37589131, PMID 37710001, PMID 39033692, PMID 39755170, PMID 39918363, PMID 40383434, PMID 41259729, PMID 42013403, PMID 42218660
2023 (4), 2018 (1), 2025 (1)